Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Masahiro Endo"'
Autor:
Taichi Miyawaki, Tateaki Naito, Kosei Doshita, Hiroaki Kodama, Mikiko Mori, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 14, Pp 2064-2074 (2022)
Abstract Background Cancer cachexia and tumor burden predict efficacies of programmed cell death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors and chemotherapy or pembrolizumab in non‐small cell lung cancer (NSCLC). There are no pre
Externí odkaz:
https://doaj.org/article/055f322f354a4bb88572f00b0542def1
Autor:
Hisao Imai, Tetsuhiko Taira, Yasushi Hisamatsu, Haruyasu Murakami, Keita Mori, Toshiaki Takahashi, Hiroaki Akamatsu, Nobuyuki Yamamoto, Akira Ono, Takashi Y. Nakajima, Hirotsugu Kenmotsu, Madoka Kimura, Masahiro Endo, Takehito Shukuya, Tateaki Naito
Publikováno v:
Thoracic Cancer. 5:121-125
Background S-1 is a novel antimetabolic agent that inhibits thymidylate synthase. The expression of thymidylate synthase is higher in squamous (Sq) non-small cell lung cancer (NSCLC) than in non-Sq NSCLC. The aim of this retrospective study was to as